DPI developer PureIMS announced that it has closed an investment round that included Boost-UP Foundation, CardusoCapital, IMDS Medical Devices, and LinesBridge Pharma Group, with funds intended mostly to support development of a levodopa DPI based on the company’s Cyclops pre-filled single use dry powder inhaler. The amount of the new investment was not specified.
The company said that it intends to develop the levodopa DPI for the treatment of OFF periods in Parkinson’s disease in the US and Europe. In addition to Levodopa Cyclops, PureIMS is also developing epinephrine, colistin, tobramycin, and amikacin delivered via the Cyclops device. The company said that with the new funding, it would also be looking for additional opportunities.
PureIMS CEO Jaap Wieling commented, “I am very pleased with the current investments which enable us to fulfill our desire to take a major step in the company’s development and to capitalize on the opportunities we see for Cyclops for a broad range of molecules and indications, with marketed compounds as well as NCE’s and NBE’s.”
Read the PureIMS press release.
